Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Bilastine 20 mg Tablets in Healthy Thai Subjects Under Fasting Conditions
TCTR20241223002Phase 3Not yet recruiting
- Sponsor
- Chulalongkorn University
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of bilastine in allergic rhinitis (AR), urticaria, sponsored by Chulalongkorn University. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
bilastine
03
Conditions
allergic rhinitis (AR)urticaria
Beyond the preview
Go deeper on TCTR20241223002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20241223002.